Request Sample Form


Phone No.*:


Service Intersted In:

Download Complete Report

Your Name*:


Contact Number*:


Service Interested In* (required)

Your Requirment*:

AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New […]

August 23rd, 2019|News|

Orphan Drug Designation granted for AZ’ Imfinzi

AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).

July 12th, 2019|News|

Imfinzi found to improve survival in small cell lung cancer

AstraZeneca has announced that its monoclonal antibody, Imfinzi (durvalumab), was found to improve overall survival at interim analysis in the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer.

June 27th, 2019|News|

AZ confirms cardiovascular safety with roxadustat results

AstraZeneca has announced top-line results from the pooled cardiovascular (CV) safety analyses of its global Phase III roxadustat programme.

May 16th, 2019|News|

AZ announces Phase I DS-8201 results

AstraZeneca has announced two Lancet Oncologypublications of its Phase I dose-expansion results of DS-8201 (trastuzumab deruxtecan) in HER2-positive metastatic breast and gastric cancer.

May 2nd, 2019|News|

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.

September 25th, 2018|News|